Loading…

Buty and the beast: the complex role of butyrate in Parkinson's disease

Parkinson's disease (PD) is a complex neurodegenerative disease which is often associated with gastrointestinal (GI) dysfunction. The GI tract is home to a wide range of microorganisms, among which bacteria, that can influence the host through various mechanisms. Products produced by these bact...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2024-04, Vol.15, p.1388401-1388401
Main Authors: Elford, Joshua D, Becht, Nanette, Garssen, Johan, Kraneveld, Aletta D, Perez-Pardo, Paula
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c420t-b32ca8b3e4ca5e6fdd9c7fd46009896d1293744a42edaee36a0d868df5ba598f3
container_end_page 1388401
container_issue
container_start_page 1388401
container_title Frontiers in pharmacology
container_volume 15
creator Elford, Joshua D
Becht, Nanette
Garssen, Johan
Kraneveld, Aletta D
Perez-Pardo, Paula
description Parkinson's disease (PD) is a complex neurodegenerative disease which is often associated with gastrointestinal (GI) dysfunction. The GI tract is home to a wide range of microorganisms, among which bacteria, that can influence the host through various mechanisms. Products produced by these bacteria can act in the gut but can also exert effects in the brain via what is now well established to be the microbiota-gut-brain axis. In those with PD the gut-bacteria composition is often found to be different to that of non-PD individuals. In addition to compositional changes, the metabolic activity of the gut-microbiota is also changed in PD. Specifically, it is often reported that key producers of short chain fatty acids (SCFAs) as well as the concentration of SCFAs themselves are altered in the stool and blood of those with PD. These SCFAs, among which butyrate, are essential nutrients for the host and are a major energy source for epithelial cells of the GI tract. Additionally, butyrate plays a key role in regulating various host responses particularly in relation to inflammation. Studies have demonstrated that a reduction in butyrate levels can have a critical role in the onset and progression of PD. Furthermore, it has been shown that restoring butyrate levels in those with PD through methods such as probiotics, prebiotics, sodium butyrate supplementation, and fecal transplantation can have a beneficial effect on both motor and non-motor outcomes of the disease. This review presents an overview of evidence for the altered gut-bacteria composition and corresponding metabolite production in those with PD, with a particular focus on the SCFA butyrate. In addition to presenting current studies regarding SCFA in clinical and preclinical reports, evidence for the possibility to target butyrate production using microbiome based approaches in a therapeutic context is discussed.
doi_str_mv 10.3389/fphar.2024.1388401
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8e5713bec5334b89ac5fe50aacfe5b6e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8e5713bec5334b89ac5fe50aacfe5b6e</doaj_id><sourcerecordid>3050174666</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-b32ca8b3e4ca5e6fdd9c7fd46009896d1293744a42edaee36a0d868df5ba598f3</originalsourceid><addsrcrecordid>eNpVkU1vEzEQhq2Kqq1C_wAH5BtcEvwdmwuiFZRKlcoBztbYHjdbNutgbxD992yTULW-zMie9_FIDyFvOFtIad2HvFlBXQgm1IJLaxXjR-SMGyPnznLx6ll_Ss5bu2fTkc5Jo07IqbTGKSf0Gbm62I4PFIZExxXSgNDGj7s2lvWmx7-0lh5pyTRMcxVGpN1Av0P91Q2tDO8aTV2bQviaHGfoG54f6oz8_Prlx-W3-c3t1fXl55t5VIKN8yBFBBskqggaTU7JxWVOyjDmrDOJCyeXSoESmABRGmDJGpuyDqCdzXJGrvfcVODeb2q3hvrgC3R-d1HqnYc6drFHb1EvuQwYtZQqWAdRZ9QMIE4lGJxYn_aszTasMUUcxgr9C-jLl6Fb-bvyx3PODFfTqjPy_kCo5fcW2-jXXYvY9zBg2TYvmWZ8qcykYkbEfjTW0lrF_PQPZ_7RqN8Z9Y9G_cHoFHr7fMOnyH9_8h-jiZ6o</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3050174666</pqid></control><display><type>article</type><title>Buty and the beast: the complex role of butyrate in Parkinson's disease</title><source>PubMed Central</source><creator>Elford, Joshua D ; Becht, Nanette ; Garssen, Johan ; Kraneveld, Aletta D ; Perez-Pardo, Paula</creator><creatorcontrib>Elford, Joshua D ; Becht, Nanette ; Garssen, Johan ; Kraneveld, Aletta D ; Perez-Pardo, Paula</creatorcontrib><description>Parkinson's disease (PD) is a complex neurodegenerative disease which is often associated with gastrointestinal (GI) dysfunction. The GI tract is home to a wide range of microorganisms, among which bacteria, that can influence the host through various mechanisms. Products produced by these bacteria can act in the gut but can also exert effects in the brain via what is now well established to be the microbiota-gut-brain axis. In those with PD the gut-bacteria composition is often found to be different to that of non-PD individuals. In addition to compositional changes, the metabolic activity of the gut-microbiota is also changed in PD. Specifically, it is often reported that key producers of short chain fatty acids (SCFAs) as well as the concentration of SCFAs themselves are altered in the stool and blood of those with PD. These SCFAs, among which butyrate, are essential nutrients for the host and are a major energy source for epithelial cells of the GI tract. Additionally, butyrate plays a key role in regulating various host responses particularly in relation to inflammation. Studies have demonstrated that a reduction in butyrate levels can have a critical role in the onset and progression of PD. Furthermore, it has been shown that restoring butyrate levels in those with PD through methods such as probiotics, prebiotics, sodium butyrate supplementation, and fecal transplantation can have a beneficial effect on both motor and non-motor outcomes of the disease. This review presents an overview of evidence for the altered gut-bacteria composition and corresponding metabolite production in those with PD, with a particular focus on the SCFA butyrate. In addition to presenting current studies regarding SCFA in clinical and preclinical reports, evidence for the possibility to target butyrate production using microbiome based approaches in a therapeutic context is discussed.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2024.1388401</identifier><identifier>PMID: 38694925</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>butyrate ; gut-brain axis ; microbiome ; Parkinson’s disease ; Pharmacology ; short-chain fatty acid</subject><ispartof>Frontiers in pharmacology, 2024-04, Vol.15, p.1388401-1388401</ispartof><rights>Copyright © 2024 Elford, Becht, Garssen, Kraneveld and Perez-Pardo.</rights><rights>Copyright © 2024 Elford, Becht, Garssen, Kraneveld and Perez-Pardo. 2024 Elford, Becht, Garssen, Kraneveld and Perez-Pardo</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c420t-b32ca8b3e4ca5e6fdd9c7fd46009896d1293744a42edaee36a0d868df5ba598f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061429/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061429/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38694925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elford, Joshua D</creatorcontrib><creatorcontrib>Becht, Nanette</creatorcontrib><creatorcontrib>Garssen, Johan</creatorcontrib><creatorcontrib>Kraneveld, Aletta D</creatorcontrib><creatorcontrib>Perez-Pardo, Paula</creatorcontrib><title>Buty and the beast: the complex role of butyrate in Parkinson's disease</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Parkinson's disease (PD) is a complex neurodegenerative disease which is often associated with gastrointestinal (GI) dysfunction. The GI tract is home to a wide range of microorganisms, among which bacteria, that can influence the host through various mechanisms. Products produced by these bacteria can act in the gut but can also exert effects in the brain via what is now well established to be the microbiota-gut-brain axis. In those with PD the gut-bacteria composition is often found to be different to that of non-PD individuals. In addition to compositional changes, the metabolic activity of the gut-microbiota is also changed in PD. Specifically, it is often reported that key producers of short chain fatty acids (SCFAs) as well as the concentration of SCFAs themselves are altered in the stool and blood of those with PD. These SCFAs, among which butyrate, are essential nutrients for the host and are a major energy source for epithelial cells of the GI tract. Additionally, butyrate plays a key role in regulating various host responses particularly in relation to inflammation. Studies have demonstrated that a reduction in butyrate levels can have a critical role in the onset and progression of PD. Furthermore, it has been shown that restoring butyrate levels in those with PD through methods such as probiotics, prebiotics, sodium butyrate supplementation, and fecal transplantation can have a beneficial effect on both motor and non-motor outcomes of the disease. This review presents an overview of evidence for the altered gut-bacteria composition and corresponding metabolite production in those with PD, with a particular focus on the SCFA butyrate. In addition to presenting current studies regarding SCFA in clinical and preclinical reports, evidence for the possibility to target butyrate production using microbiome based approaches in a therapeutic context is discussed.</description><subject>butyrate</subject><subject>gut-brain axis</subject><subject>microbiome</subject><subject>Parkinson’s disease</subject><subject>Pharmacology</subject><subject>short-chain fatty acid</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1vEzEQhq2Kqq1C_wAH5BtcEvwdmwuiFZRKlcoBztbYHjdbNutgbxD992yTULW-zMie9_FIDyFvOFtIad2HvFlBXQgm1IJLaxXjR-SMGyPnznLx6ll_Ss5bu2fTkc5Jo07IqbTGKSf0Gbm62I4PFIZExxXSgNDGj7s2lvWmx7-0lh5pyTRMcxVGpN1Av0P91Q2tDO8aTV2bQviaHGfoG54f6oz8_Prlx-W3-c3t1fXl55t5VIKN8yBFBBskqggaTU7JxWVOyjDmrDOJCyeXSoESmABRGmDJGpuyDqCdzXJGrvfcVODeb2q3hvrgC3R-d1HqnYc6drFHb1EvuQwYtZQqWAdRZ9QMIE4lGJxYn_aszTasMUUcxgr9C-jLl6Fb-bvyx3PODFfTqjPy_kCo5fcW2-jXXYvY9zBg2TYvmWZ8qcykYkbEfjTW0lrF_PQPZ_7RqN8Z9Y9G_cHoFHr7fMOnyH9_8h-jiZ6o</recordid><startdate>20240417</startdate><enddate>20240417</enddate><creator>Elford, Joshua D</creator><creator>Becht, Nanette</creator><creator>Garssen, Johan</creator><creator>Kraneveld, Aletta D</creator><creator>Perez-Pardo, Paula</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240417</creationdate><title>Buty and the beast: the complex role of butyrate in Parkinson's disease</title><author>Elford, Joshua D ; Becht, Nanette ; Garssen, Johan ; Kraneveld, Aletta D ; Perez-Pardo, Paula</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-b32ca8b3e4ca5e6fdd9c7fd46009896d1293744a42edaee36a0d868df5ba598f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>butyrate</topic><topic>gut-brain axis</topic><topic>microbiome</topic><topic>Parkinson’s disease</topic><topic>Pharmacology</topic><topic>short-chain fatty acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elford, Joshua D</creatorcontrib><creatorcontrib>Becht, Nanette</creatorcontrib><creatorcontrib>Garssen, Johan</creatorcontrib><creatorcontrib>Kraneveld, Aletta D</creatorcontrib><creatorcontrib>Perez-Pardo, Paula</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elford, Joshua D</au><au>Becht, Nanette</au><au>Garssen, Johan</au><au>Kraneveld, Aletta D</au><au>Perez-Pardo, Paula</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Buty and the beast: the complex role of butyrate in Parkinson's disease</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2024-04-17</date><risdate>2024</risdate><volume>15</volume><spage>1388401</spage><epage>1388401</epage><pages>1388401-1388401</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Parkinson's disease (PD) is a complex neurodegenerative disease which is often associated with gastrointestinal (GI) dysfunction. The GI tract is home to a wide range of microorganisms, among which bacteria, that can influence the host through various mechanisms. Products produced by these bacteria can act in the gut but can also exert effects in the brain via what is now well established to be the microbiota-gut-brain axis. In those with PD the gut-bacteria composition is often found to be different to that of non-PD individuals. In addition to compositional changes, the metabolic activity of the gut-microbiota is also changed in PD. Specifically, it is often reported that key producers of short chain fatty acids (SCFAs) as well as the concentration of SCFAs themselves are altered in the stool and blood of those with PD. These SCFAs, among which butyrate, are essential nutrients for the host and are a major energy source for epithelial cells of the GI tract. Additionally, butyrate plays a key role in regulating various host responses particularly in relation to inflammation. Studies have demonstrated that a reduction in butyrate levels can have a critical role in the onset and progression of PD. Furthermore, it has been shown that restoring butyrate levels in those with PD through methods such as probiotics, prebiotics, sodium butyrate supplementation, and fecal transplantation can have a beneficial effect on both motor and non-motor outcomes of the disease. This review presents an overview of evidence for the altered gut-bacteria composition and corresponding metabolite production in those with PD, with a particular focus on the SCFA butyrate. In addition to presenting current studies regarding SCFA in clinical and preclinical reports, evidence for the possibility to target butyrate production using microbiome based approaches in a therapeutic context is discussed.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38694925</pmid><doi>10.3389/fphar.2024.1388401</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2024-04, Vol.15, p.1388401-1388401
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8e5713bec5334b89ac5fe50aacfe5b6e
source PubMed Central
subjects butyrate
gut-brain axis
microbiome
Parkinson’s disease
Pharmacology
short-chain fatty acid
title Buty and the beast: the complex role of butyrate in Parkinson's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T02%3A45%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Buty%20and%20the%20beast:%20the%20complex%20role%20of%20butyrate%20in%20Parkinson's%20disease&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Elford,%20Joshua%20D&rft.date=2024-04-17&rft.volume=15&rft.spage=1388401&rft.epage=1388401&rft.pages=1388401-1388401&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2024.1388401&rft_dat=%3Cproquest_doaj_%3E3050174666%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-b32ca8b3e4ca5e6fdd9c7fd46009896d1293744a42edaee36a0d868df5ba598f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3050174666&rft_id=info:pmid/38694925&rfr_iscdi=true